BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/2/2026 6:21:41 AM | Browse: 2 | Download: 0
 |
Received |
|
2026-03-02 03:33 |
|
Peer-Review Started |
|
2026-03-02 03:34 |
|
First Decision by Editorial Office Director |
|
2026-03-04 08:59 |
|
Return for Revision |
|
2026-03-04 08:59 |
|
Revised |
|
2026-03-18 07:00 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-19 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-19 11:42 |
|
Articles in Press |
|
2026-05-19 11:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-30 10:07 |
|
Publish the Manuscript Online |
|
2026-09-02 06:21 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Minireviews |
| Article Title |
Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Soha Elatrebi, Rowan Abuyadek, Sohaila Mohamed Mohamed Abdelbar, Muhammad S Ahmad, Mohamed Ayyad, Muhammad AbdelAziz Quoritem, Rodaina Osama Abdel Majid, Manar Arafat, Ahmed Amgad and Amr Alnagar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amr Alnagar, PhD, Department of General Surgery, University Hospitals of Birmingham, 6 Chamberlain Road, Birmingham B9 5SS, United Kingdom. amr.alnagar@nhs.net |
| Key Words |
Liver transplantation; Obesity; Metabolic syndrome; Steatosis; Weight loss |
| Core Tip |
While liver transplantation can be life-saving for end-stage liver diseases, it can exacerbate metabolic issues due to underlying pathology and immunosuppressive regimens. A thorough management plan is essential to prevent complications like metabolic dysfunction-associated steatotic liver disease, chronic renal dysfunction, and diabetes, ultimately improving prognosis and quality of life. glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists have gained United States Food and Drug Administration approval for long-term weight management, but their long-term safety, optimal dosing, and effectiveness in transplant recipients remain underexplored. This review addresses the pathophysiology, risk factors, and burden of metabolic complications in liver transplant recipients while evaluating the potential role of GLP-1 and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists for managing these issues. |
| Publish Date |
2026-09-02 06:21 |
| Citation |
Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, Arafat M, Amgad A, Alnagar A. Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. World J Transplant 2026; 16(3): 120572
|
| URL |
https://www.wjgnet.com/2220-3230/full/v16/i3/120572.htm |
| DOI |
https://doi.org/10.5500/wjt.120572 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
